※一部利用できない機能があります
Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
- フォーマット:
- 論文
- 責任表示:
- Takeshita, Yumie ; Takamura, Toshinari ; Kita, Yuki ; Otoda, Toshiki ; Kato, Ken-ichiro ; Wakakuri, Hitomi ; Yamada, Masayuki ; Misu, Hirofumi ; Matsushima, Yukiko ; Kaneko, Shuichi
- 言語:
- 英語
- 出版情報:
- Blackwell Publishing, 2015-03-01
- 著者名:
Takeshita, Yumie Takamura, Toshinari Kita, Yuki Otoda, Toshiki Kato, Ken-ichiro Wakakuri, Hitomi Yamada, Masayuki Misu, Hirofumi Matsushima, Yukiko Kaneko, Shuichi - 掲載情報:
- Journal of Diabetes Investigation
- ISSN:
- 2040-1116
- 巻:
- 6
- 通号:
- 2
- 開始ページ:
- 193
- 終了ページ:
- 200
- バージョン:
- publisher
- 概要:
- Introduction: A step-up strategy for dipeptidyl peptidase (DPP)-4 inhibitor-based regimens has not yet been established. In addition, similarities and differences between DPP-4 inhibitors and glucagon-like peptide (GLP)-1 receptor agonists remain to be elucidated in humans. We investigated the pleiotropic effects of vildagliptin vs liraglutide in patients with type 2 diabetes on sitagliptin-based regimens in an open-label, randomized, clinical … trial. Materials and Methods: A total of 122 patients with type 2 diabetes that was inadequately controlled by sitagliptin-based regimens were randomly assigned to either vildagliptin (50 mg, twice daily) or liraglutide treatment (0.9 mg, once daily) for 12 weeks. The primary outcomes were glycated hemoglobin and body mass index. Results: Both vildagliptin and liraglutide significantly lowered glycated hemoglobin within 12 weeks after switching from sitagliptin, but liraglutide produced a greater reduction (-0.67 ± 0.12% vs -0.36 ± 0.53%). Liraglutide lowered body mass index, whereas vildagliptin did not affect body mass index. Vildagliptin lowered fasting C-peptide immunoreactivity, but liraglutide did not. Vildagliptin increased serum levels of adiponectin, arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, whereas liraglutide had no effect on these levels. Quality of life, assessed using the diabetes treatment satisfaction questionnaire, was not impaired in either group. The most common adverse events were gastrointestinal symptoms, which occurred with similar frequencies in both groups. Conclusions: Vildagliptin-mediated improvements in glycemic control did not correlate with indices for insulin secretion and insulin sensitivity. Switching from sitagliptin to liraglutide is useful in managing hyperglycemia and weight. Each agent exerts unique pleiotropic effects. This trial was registered with the University Hospital Medical Information Network Clinical Trials Registry (no. 000004953). © 2014 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd. 続きを見る
- URL:
- http://hdl.handle.net/2297/45567
類似資料:
日本内科学会 = The Japanese Society of Internal Medicine | |
Public Library of Science | |
日本内科学会 = the Japanese Society of Internal Medicine | |